Archive for January, 2020

  • Gene expression analysis method has been validated by a commercial laboratory

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method …

    by

  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that over 200…

    by

  • The Phase 1/2a study ISO-CC-005 is completed

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment…

    by

  • Presentation and poster at ASCO Gastrointestinal Cancers Symposium

    Isofol is attending the event and will present details in the ongoing global Phase 3 AGENT clinical study (ISO-CC-007) Presentation…

    by

  • The first patient included in Australia in Isofol’s Phase 3 AGENT study

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by